Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough SummitBusiness Wire • 09/10/24
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and HaemostasisBusiness Wire • 08/29/24
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 08/14/24
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business UpdatesBusiness Wire • 08/08/24
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse PopulationsBusiness Wire • 06/17/24
Rallybio Reports First Quarter 2024 Financial Results and Provides Business UpdatesBusiness Wire • 05/09/24
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual MeetingBusiness Wire • 04/17/24
Rallybio partners with J&J to advance therapies targeting rare fetal diseaseProactive Investors • 04/11/24
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)Business Wire • 04/10/24
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual MeetingBusiness Wire • 04/01/24
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024Business Wire • 01/04/24
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5Business Wire • 12/20/23